Zomedica Corp. ZOMDF
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About ZOMDF
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Zomedica Corp. is a veterinary health company focused on companion animal diagnostics, monitoring, and therapeutic products for veterinarians and animal health professionals. The company operates within the broader animal health and veterinary medical technology industries, with a primary emphasis on point-of-care diagnostics and practice-support technologies for dogs, cats, and other companion animals. Its principal revenue drivers include diagnostic platforms, consumable assay cartridges, imaging systems, and pulse-based therapeutic devices used in veterinary clinics.
The company evolved from an early-stage diagnostic development business into a broader veterinary technology platform through acquisitions and product expansion. Zomedica became widely known through the commercialization of its TRUFORMA diagnostic platform and later expanded into imaging, therapeutic, and monitoring solutions through acquisitions including PulseVet, Assisi Animal Health, and VetGuardian. The company’s strategy has centered on building an integrated veterinary portfolio that combines recurring consumable revenue with durable medical equipment and practice workflow technologies.
Business Operations
Zomedica generates revenue primarily through the sale of veterinary diagnostic instruments, therapeutic devices, imaging systems, software-enabled monitoring products, and recurring consumables. Its operations are centered around companion animal healthcare in North America, particularly the United States veterinary clinic market. Key operating businesses and product platforms include TRUFORMA, a point-of-care diagnostic platform; PulseVet, focused on electrohydraulic shock wave therapy; Assisi Animal Health, which develops targeted pulsed electromagnetic field therapy products; and VetGuardian, a contactless vital-sign monitoring system for hospitalized animals.
The company’s operations include product development, manufacturing coordination, commercialization, direct sales activities, and distributor-supported market access. Zomedica has leveraged acquisitions to broaden its technology portfolio and increase access to veterinary practices across diagnostics, therapeutics, and monitoring categories. While the company’s commercial concentration remains primarily domestic, its technologies have been positioned for broader international veterinary adoption through distribution relationships and expanding product availability.
Strategic Position & Investments
Zomedica’s strategic direction has focused on creating a diversified veterinary health platform capable of serving multiple clinical functions within companion animal practices. The company has pursued growth through acquisitions, product integration, and expansion of recurring revenue streams tied to consumables and ongoing treatment usage. Major investments have included the acquisition and development of PulseVet, which strengthened the company’s therapeutic offerings, as well as the acquisitions of Assisi Animal Health and VetGuardian, which expanded its capabilities in rehabilitation, pain management, and patient monitoring.
The company has emphasized technologies that support in-clinic diagnostics, non-invasive treatment options, and workflow efficiency for veterinary professionals. Zomedica’s positioning within the companion animal market aligns with broader industry trends including increased pet healthcare spending, advanced veterinary treatment adoption, and demand for point-of-care clinical tools. The company has also invested in expanding commercial infrastructure and integrating acquired businesses into a unified veterinary product ecosystem.
Geographic Footprint
Zomedica is headquartered in Ann Arbor, Michigan, and conducts the majority of its commercial operations in the United States. Its products are marketed primarily to veterinary clinics, specialty hospitals, and animal health providers serving companion animals throughout North America. The company’s operational and sales footprint has historically been concentrated in the U.S. veterinary market, which remains its principal source of revenue.
Through distributor relationships and acquired product lines, Zomedica has established exposure to select international markets, although publicly available information indicates that its primary commercial influence remains domestic relative to larger multinational animal health companies. Its technologies and acquired brands have potential applicability across broader global veterinary markets, particularly in regions with advanced companion animal care infrastructure.
Leadership & Governance
Zomedica’s leadership has focused on expanding the company from a single-product diagnostic business into a diversified veterinary technology organization. Management strategy has emphasized acquisition-driven growth, operational integration, and building long-term recurring revenue through consumables and clinical-use technologies. The company operates under a publicly traded corporate governance structure with executive leadership and board oversight aligned with shareholder reporting requirements.
Key executives publicly associated with the company include:
- Larry Heaton – Chief Executive Officer
- Peter Donato – Chief Financial Officer
- Robert Cohen – Executive Chairman
Data regarding additional current executive appointments and governance roles is inconclusive based on available public sources.